Abeona Therapeutics Inc. (ABEO) |
|
2.44 -0.01 (-0.41%)
|
03-22 15:11 |
|
Open: |
2.46 |
Pre. Close: |
2.45 |
|
High:
|
2.49 |
Low:
|
2.4 |
|
Volume:
|
26,457 |
Market Cap:
|
42(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 2:45:24 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 3.4 One year: 3.93 |
| Support: |
Support1: 2.19 Support2: 1.82 |
| Resistance: |
Resistance1: 2.91 Resistance2: 3.36 |
| Pivot: |
2.6  |
| Moving Average: |
MA(5): 2.42  MA(20): 2.52
MA(100): 3.04 MA(250): 3.94 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 15.2 %D(3): 15.8 |
| RSI: |
RSI(14): 46.3 |
| 52-week: |
High: 9.25 Low: 0.15 |
| Average Vol(K): |
3-Month: 223 (K) 10-Days: 159 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ABEO ] has closed above bottom band by 31.4%. Bollinger Bands are 7.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.54 - 2.56 |
2.56 - 2.57 |
|
Low:
|
2.31 - 2.32 |
2.32 - 2.34 |
|
Close:
|
2.42 - 2.45 |
2.45 - 2.47 |
|
Company Description |
|
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York. |
Headline News |
Thu, 16 Mar 2023
Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting - Yahoo Finance
Tue, 07 Mar 2023
Abeona Therapeutics Inc (ABEO) Stock: What Does the Chart Say Tuesday? - InvestorsObserver
Wed, 08 Feb 2023
Summit Therapeutics Inc (SMMT) Stock Decreases -31.05% This Week; Should You Buy? - InvestorsObserver
Wed, 08 Feb 2023
Is Onconova Therapeutics Inc (ONTX) Stock a Smart Value? - InvestorsObserver
Mon, 14 Nov 2022
Abeona Therapeutics Reports Third Quarter 2022 Financial Results - GlobeNewswire
Thu, 03 Nov 2022
Abeona Therapeutics Announces $35 Million Private Placement ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
17 (M) |
|
% Held by Insiders
|
9.69e+006 (%) |
|
% Held by Institutions
|
5.4 (%) |
|
Shares Short
|
524 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-4.429e+007 |
|
EPS Est Next Qtl
|
-0.19 |
|
EPS Est This Year
|
-0.7 |
|
EPS Est Next Year
|
-0.77 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
91.9 |
|
Return on Equity (ttm)
|
-37.6 |
|
Qtrly Rev. Growth
|
4.35e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-150.58 |
|
EBITDA (p.s.)
|
-2.63193e+007 |
|
Qtrly Earnings Growth
|
-17.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-60 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.02 |
|
Price to Cash Flow
|
1.44 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
460480 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
